Alnylam pharmaceuticals, inc. (ALNY)
CashFlow / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14Sep'14Jun'14Mar'14Dec'13Sep'13Jun'13Mar'13Dec'12Sep'12Jun'12Mar'12Dec'11Sep'11Jun'11Mar'11Dec'10Sep'10Jun'10Mar'10
Cash flows from operating activities:
Net loss

-886,422

-886,116

-821,372

-858,119

-802,198

-761,497

-692,283

-569,938

-524,798

-490,874

-461,581

-442,715

-414,424

-410,108

-387,895

-360,616

-342,270

-290,073

-220,741

-187,938

-160,229

-360,395

-371,363

-357,060

-331,155

-89,225

-119,056

-108,872

-103,659

-106,014

-58,129

-51,864

-52,732

-57,649

-50,276

-46,669

-47,477

-43,515

0

0

0

Non-cash adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization

20,950

17,175

21,159

31,786

15,908

15,248

8,067

11,249

12,076

11,898

12,671

12,584

13,529

15,130

17,181

18,951

19,961

19,050

17,322

15,169

13,016

11,926

11,212

10,859

10,702

10,229

9,626

9,147

9,041

9,035

8,248

7,225

5,907

5,125

5,179

5,183

5,119

4,941

0

0

0

Amortization and interest accretion related to operating leases

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deferred income taxes

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

10,742

0

0

0

Stock-based compensation

177,387

174,841

136,617

178,562

170,200

157,752

156,896

94,897

96,686

92,819

86,353

75,979

67,765

75,528

70,397

66,664

61,027

45,783

43,701

38,205

35,706

33,061

25,029

27,522

23,219

20,703

18,019

12,560

12,279

12,360

13,720

14,592

15,710

16,676

16,806

17,059

17,913

19,118

0

0

0

Charge for 401(k) company stock match

-

-

-

-

-

-

0

0

2,693

-

2,040

1,800

1,727

1,507

1,411

1,244

1,068

984

954

1,545

1,096

692

1,313

364

172

449

-1,025

-823

-340

-364

405

426

722

488

1,290

1,040

224

495

0

0

0

Unrealized gain on marketable equity securities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Equity in loss of joint venture (Regulus Therapeutics Inc.)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-4,522

-4,595

-3,449

-3,322

-3,505

-3,467

-4,226

-7,133

-7,639

0

0

0

Realized loss on sale of marketable equity securities

-

-

-

-

-

-

-

-

-

-

0

0

272

-

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

255

0

0

0

-

-

-

-

-

-

-

-

Other

-1,456

-3,191

0

0

0

-

-

-

-

4,379

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Benefit from intraperiod tax allocation

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-22,770

-40,209

-15,097

-17,434

-20,003

-2,695

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

In-process research and development

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Changes in operating assets and liabilities:
Accounts receivable, net

42,079

24,238

45,115

27,733

-16,967

-15,242

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Proceeds from landlord lease incentive for tenant improvements

-17,784

-30,170

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-204

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

Inventory

37,229

32,411

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Billed and unbilled collaboration receivables

-

-

-

-

-

-

-

-

-

-

-

0

10,643

-

7,016

111

-1,293

-31,639

7,746

9,314

9,943

35,689

-225

-371

-394

4,144

-1,309

-3,925

-1,634

-1,364

-109

3,077

1,042

-1,982

-2,854

-5,050

-3,355

-2,594

0

0

0

Income taxes receivable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-10,669

0

0

0

-

-

-

-

Prepaid expenses and other assets

33,012

22,042

14,604

8,943

16,515

35,067

52,784

41,774

51,959

20,711

4,515

-119

-442

5,276

2,207

7,323

5,651

6,820

6,466

4,559

4,509

5,829

5,923

6,066

4,911

1,356

-917

-2,743

-3,768

-1,780

608

1,694

2,171

-2,731

-1,523

-944

-190

2,738

0

0

0

Accounts payable, accrued expenses and other liabilities

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Accounts payable

-

-

-

-

-

-

0

0

-2,914

-

-5,711

5,362

-1,316

10,098

1,099

-719

1,273

1,676

8,781

7,524

10,969

8,840

2,342

1,483

1,412

1,832

-2,365

-985

-1,234

-1,736

-393

-2,430

-1,461

-3,512

-1,075

-2,449

-1,188

-3,177

0

0

0

Income taxes payable

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-5,516

0

0

0

Accrued expenses and other liabilities

-

-

-

-

-

-

0

0

30,656

-

9,914

5,552

4,123

10,673

17,567

14,969

10,470

6,343

-2,644

-22

-3,083

9,122

4,967

6,825

7,110

1,547

-2,398

-9,221

-5,633

-3,591

3,394

4,134

929

2,457

1,839

4,131

3,639

651

0

0

0

Deferred revenue

389,055

392,251

398,471

389,444

-40,411

-12,616

-3,611

20

28,937

1,848

-93

8,178

11,908

14,615

11,332

11,420

10,672

1,904

15,792

3,166

-6,130

-7,786

-23,589

-20,196

-21,283

-6,201

9,152

27,743

18,744

-8,562

-44,352

-77,390

-80,426

-70,255

-70,399

-72,215

-70,931

-60,705

0

0

0

Operating lease liability

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash used in operating activities

-336,078

-278,427

-232,904

-204,080

-595,462

-562,616

-515,203

-459,758

-438,120

-382,786

-358,079

-335,252

-324,408

-307,701

-282,428

-261,257

-246,508

-189,140

-172,711

-159,052

-150,221

-165,641

-151,375

-132,384

-109,361

-68,657

-115,200

-88,273

-86,365

-115,609

-71,856

-106,093

-110,978

-87,068

-82,297

-77,310

-75,045

-84,341

0

0

0

Cash flows from investing activities:
Purchases of property, plant and equipment

115,724

140,156

138,864

148,215

149,679

126,887

110,102

90,371

89,314

104,209

103,360

97,980

97,950

64,557

47,777

33,956

13,599

12,950

13,377

10,095

10,683

8,961

6,313

4,068

2,595

4,006

3,814

8,593

9,884

8,348

8,186

2,722

1,526

1,291

1,905

2,707

3,663

4,732

0

0

0

Purchases of restricted investments and increase in restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,471

0

0

0

-

-

-

-

-

-

-

-

162

0

0

0

-

-

-

-

-

-

-

-

Purchases of marketable debt securities

2,215,338

2,075,925

1,557,293

1,295,822

1,002,609

1,104,046

1,383,816

1,309,060

1,175,087

903,457

655,673

638,502

681,552

759,310

751,465

574,165

690,787

1,033,843

1,023,143

1,026,935

997,794

977,775

881,781

858,387

664,826

364,305

416,654

394,453

345,996

277,129

270,966

286,460

369,535

293,115

320,801

372,156

351,152

390,473

0

0

0

Sales and maturities of marketable securities

1,911,321

1,775,404

1,718,294

1,602,425

1,677,524

1,518,703

1,252,136

924,297

644,150

597,305

729,651

812,873

1,020,172

1,116,458

1,070,898

959,852

852,573

726,943

658,649

648,395

498,403

462,922

398,893

332,844

312,976

237,806

277,428

280,363

294,007

289,013

259,959

288,387

365,302

376,365

431,460

452,050

402,402

413,043

0

0

0

Purchases of restricted investments

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Deposit for manufacturing facility

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payment for asset acquisition

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

25,000

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net cash provided by investing activities

-406,641

-417,677

52,137

158,388

510,411

272,945

-136,607

-369,959

-500,251

-290,361

-29,382

76,391

99,727

142,591

120,473

200,548

137,947

-321,321

-378,159

-388,923

-510,362

-548,814

-514,201

-554,611

-379,445

-130,505

-143,040

-122,683

-61,873

3,374

-19,355

-957

-5,921

81,959

108,754

77,187

47,587

17,838

0

0

0

Cash flows from financing activities:
Proceeds from exercise of stock options and other types of equity, net

116,122

71,284

36,320

39,460

32,407

65,470

102,377

118,976

123,210

83,885

45,037

20,505

15,072

14,127

17,233

16,640

19,395

31,137

32,279

33,504

31,445

29,420

30,659

36,802

35,646

28,743

20,816

14,116

10,762

6,971

6,241

1,742

1,576

738

998

1,051

2,137

2,670

0

0

0

Offering proceeds, net of costs

0

381,900

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

496,400

0

0

0

-

-

-

-

173,572

173,572

173,572

173,572

86,800

0

0

0

-

-

-

-

-

-

-

-

Proceeds from issuance of common stock

-

-

-

-

-

-

-

-

-

-

-

-

-

14,301

14,301

14,301

14,301

89,018

89,018

89,018

89,018

723,037

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Payments for repurchase of common stock for employee tax withholding

-

-

-

-

-

-

-

0

776

-

543

580

590

596

0

0

0

-

-

-

-

15,992

0

0

0

-

-

-

-

359

0

0

0

-

-

-

-

-

-

-

-

Net cash provided by financing activities

486,122

823,184

788,220

821,908

414,879

65,470

767,040

782,966

1,163,697

1,124,891

421,025

396,456

164,482

177,832

181,218

180,523

33,259

616,177

617,367

618,510

616,574

736,465

736,457

742,747

741,591

200,926

194,242

187,657

184,303

93,412

92,713

88,214

88,048

738

998

1,051

3,130

3,663

0

0

0

Effect of exchange rate changes on cash, cash equivalents and restricted cash

-714

-83

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Net (decrease) increase in cash, cash equivalents and restricted cash

-257,311

126,997

607,004

776,213

329,828

-224,201

115,230

-46,751

225,326

451,744

33,564

137,595

-60,199

12,722

19,263

119,814

-75,302

105,716

66,497

70,535

-44,009

22,010

70,881

55,752

252,785

1,764

-63,998

-23,299

36,065

-18,823

1,502

-18,836

-28,851

-4,371

27,455

928

-24,357

-62,869

0

0

0

Supplemental disclosure of noncash investing and financing activities:
Capital expenditures included in accounts payable and accrued expenses

8,462

14,876

32,458

35,879

35,870

33,274

0

0

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Lease liabilities arising from obtaining right-of-use assets

0

-

-

-

0

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-